Inovio Pharmaceuticals Shares Surge Following FDA Approval of Voceryq for RRP
Inovio Pharmaceuticals (INO) experienced a significant surge in after-hours trading, rising approximately 280% following news that the U.S. Food and Drug Administration (FDA) has approved its product, Voceryq. The treatment is indicated for patients suffering from recurrent respiratory papillomatosis (RRP), a rare disease. This approval marks a major regulatory milestone for Inovio, providing a new therapeutic option for RRP patients. The market reaction reflects high investor confidence in the company's ability to bring specialized gene therapies to commercial availability.